Pharmacokinetic and pharmacogenomic considerations in managing use of nirmatrelvir-ritonavir and molnupiravir and dermatological treatments. | Ann Acad Med Singap;51(12): 752-754, 2022 12. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Pharmacokinetic and pharmacogenomic considerations in managing use of nirmatrelvir-ritonavir and molnupiravir and dermatological treatments.

Chen, Sylvia; Leong, Wai Fook; Lee, Sze Sing; Chowbay, Balram.

Chen S; Clinical Pharmacology Laboratory, Division of Cellular & Molecular Research, National Cancer Centre Singapore, Singapore.

Ann Acad Med Singap ; 51(12): 752-754, 2022 12.

Article in English | MEDLINE | ID: covidwho-2172084

Subject(s)

Pharmacogenetics; Ritonavir; Humans; Ritonavir/therapeutic use; Hydroxylamines; Antiviral Agents/therapeutic use

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmacogenetics / Ritonavir Limits: Humans Language: English Journal: Ann Acad Med Singap Year: 2022 Document Type: Article Affiliation country: Annals-acadmedsg.2022430

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmacogenetics / Ritonavir Limits: Humans Language: English Journal: Ann Acad Med Singap Year: 2022 Document Type: Article Affiliation country: Annals-acadmedsg.2022430